~P,/ q ' h c C(:)I '~: Rcp.)lt~ ( " 1 9 9 8 It is 10 years, to the month, since Richard Lock, then editor of the BMJ, published the results of a personal survey, "Misconduct in medical research: does it exist in Britain?" Of 80 senior academics, "over half of the correspondents knew of some instance of medical misconduct-most encountered first hand, although a sizeable minority were well authenticated secondhand instances and there were a few rumours as well". Lock concluded that research fraud was flourishing in Britain .... and that action should be taken to tackle the problem by establishing an agency like the Office of Scientific Integrity in the USA "to allay professional and public alarm". Although the UK General Medical Council has been busy with fraudsters since Lock threw down the gauntlet, editors of biomedical journals know that the GMC sees only the tip of an iceberg, the magnitude of which is quite unknown. However, 1998 witnessed a notable gearing up of activity in relation to publication ethics and research fraud, much of which was driven by journal editors. Early in the year the BMJ ran a series of articles on "informed consent in medical research". The Committee on Publication Ethics (COPE) published its first report, which included the proceedings of its first meeting "Research misconduct: how shouldeditors respond?" and synopses of 22 cases that were being considered by the committee. To date the committee has considered 41 cases of suspected research misconduct. The report attracted attention in the daily press on both sides of the Atlantic, including a substantial piece in the New York Times. To coincide with the publication of the COPE report, the BMJ published a further series of articles on "Dealing with research misconduct in the UK". This included views from experts in the USA, Denmark, the UK, and a view from the Medical Research Council. Some authors favoured a move to set up an independent agency to investigate cases of suspected fraud whereas others were more cautious. As always, sensitivities about intrusion crept into the debate, together with concerns about the loss of professional self-regulation. There is a sense among editors that the available approaches to selfregulation are not working and that alternatives must be sought. The GMC, for example, has no jurisdiction over non-clinical scientists. As the summer progressed, the temperature continued to rise with a volume of ffAMA being devoted to the proceedings of the Prague Congress on biomedical peer review. The ethics of authorship, conflict of interest, bias, and quality of peer review were all debated. Retraction of papers was also considered. A search of Medline from 1966 to August 1997 revealed that 235 articles had been retracted, 86 of which were deemed to be due to
Read full abstract